Stockreport

Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights [Yahoo! Finance]

Relay Therapeutics, Inc.  (RLAY) 
PDF Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Ka-mutated HR+/HER2- metastatic breast cancer Approximately $750 million in cash, cash equival [Read more]